MX365321B - Métodos para el tratamiento de neutropenia mediante agonistas retinoides. - Google Patents

Métodos para el tratamiento de neutropenia mediante agonistas retinoides.

Info

Publication number
MX365321B
MX365321B MX2014014930A MX2014014930A MX365321B MX 365321 B MX365321 B MX 365321B MX 2014014930 A MX2014014930 A MX 2014014930A MX 2014014930 A MX2014014930 A MX 2014014930A MX 365321 B MX365321 B MX 365321B
Authority
MX
Mexico
Prior art keywords
methods
treating neutropenia
neutropenia
retinoid agonists
subject
Prior art date
Application number
MX2014014930A
Other languages
English (en)
Other versions
MX2014014930A (es
Inventor
Wu Lingtao
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Publication of MX2014014930A publication Critical patent/MX2014014930A/es
Publication of MX365321B publication Critical patent/MX365321B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención provee métodos para el tratamiento de la neutropenia en un sujeto que lo necesita que comprende la administración de una composición que comprende un agonista de retinoide y la administracion de una cantidad eficaz de la composición al sujeto para tratar la neutropenia, para así tratar la neutropenia en el sujeto que lo necesita.
MX2014014930A 2012-06-07 2013-06-07 Métodos para el tratamiento de neutropenia mediante agonistas retinoides. MX365321B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
PCT/US2013/044828 WO2013185105A1 (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Publications (2)

Publication Number Publication Date
MX2014014930A MX2014014930A (es) 2015-07-06
MX365321B true MX365321B (es) 2019-05-29

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014930A MX365321B (es) 2012-06-07 2013-06-07 Métodos para el tratamiento de neutropenia mediante agonistas retinoides.

Country Status (14)

Country Link
US (1) US11116738B2 (es)
EP (1) EP2858636B1 (es)
JP (1) JP6295249B2 (es)
KR (1) KR102083046B1 (es)
CN (1) CN104519879B (es)
AU (1) AU2013270674B2 (es)
BR (1) BR112014030279A2 (es)
CA (1) CA2874850A1 (es)
ES (1) ES2691493T3 (es)
HK (1) HK1208630A1 (es)
MX (1) MX365321B (es)
NZ (1) NZ702415A (es)
RU (1) RU2650962C2 (es)
WO (1) WO2013185105A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702415A (en) 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
EP2969031A4 (en) 2013-03-15 2017-03-08 Avisenna Cosmetics LLC Topical compositions for reducing aging effects
RU2016136833A (ru) 2014-02-18 2018-03-22 Чилдрен'З Хоспитал Лос Анджелес Композиции и способы для лечения нейтропении
EP3967305A1 (en) 2015-03-31 2022-03-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2018067946A1 (en) * 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody
WO2019147187A1 (en) * 2018-01-26 2019-08-01 Agency For Science, Technology And Research Neutrophil subtypes
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
AU5611398A (en) 1996-12-19 1998-07-15 American Cyanamid Company Method of treating or inhibiting neutropenia
MXPA03002046A (es) 2000-09-08 2003-07-24 Massachusetts Inst Technology Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
TW200505408A (en) 2003-05-16 2005-02-16 Kyowa Hakko Kogyo Kk Agent for preventing and/or treating tissue disruption-accompanied diseases
EP1621191A1 (en) 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
CN101094684A (zh) 2004-08-13 2007-12-26 阿诺麦德股份有限公司 用趋化因子的组合活化祖细胞/干细胞
AU2005310888B2 (en) 2004-12-02 2011-01-06 Venus Remedies Limited Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection
US20090111786A1 (en) 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
JP2009537540A (ja) * 2006-05-16 2009-10-29 ビテ ファーマシューティカルズ， インコーポレイテッド 化学療法および／または放射線療法の副作用を処置するためのｒａｒアンタゴニストまたはｒａｒインバースアゴニストの使用
US8252837B2 (en) 2007-03-30 2012-08-28 Tmrc Co., Ltd. Tamibarotene capsule preparation
EA201070687A1 (ru) * 2007-12-06 2010-12-30 Си Эс Эл ЛИМИТЕД Способ ингибирования лейкозных стволовых клеток
US8580516B2 (en) 2008-09-05 2013-11-12 University Of Chicago Methods and compositions for direct detection of DNA damage
JP2013508352A (ja) 2009-10-19 2013-03-07 ライラ ニュートラシューティカルズ アセトゲニンを含む抽出物、フラクションおよび組成物ならびにそれらの応用
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
US9574179B2 (en) 2011-02-08 2017-02-21 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
JP6242868B2 (ja) * 2012-05-08 2017-12-06 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
NZ702415A (en) 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
RU2016136833A (ru) 2014-02-18 2018-03-22 Чилдрен'З Хоспитал Лос Анджелес Композиции и способы для лечения нейтропении

Also Published As

Publication number Publication date
CN104519879A (zh) 2015-04-15
AU2013270674A1 (en) 2014-12-18
JP6295249B2 (ja) 2018-03-14
US11116738B2 (en) 2021-09-14
WO2013185105A1 (en) 2013-12-12
KR20150035983A (ko) 2015-04-07
RU2650962C2 (ru) 2018-04-18
NZ702415A (en) 2016-04-29
EP2858636A1 (en) 2015-04-15
RU2014153988A (ru) 2016-07-27
US20150164836A1 (en) 2015-06-18
CA2874850A1 (en) 2013-12-12
JP2015523346A (ja) 2015-08-13
AU2013270674B2 (en) 2017-12-07
MX2014014930A (es) 2015-07-06
EP2858636B1 (en) 2018-09-05
CN104519879B (zh) 2018-10-02
BR112014030279A2 (pt) 2017-09-12
EP2858636A4 (en) 2016-06-01
KR102083046B1 (ko) 2020-02-28
ES2691493T3 (es) 2018-11-27
HK1208630A1 (en) 2016-03-11

Similar Documents

Publication Publication Date Title
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX2016002077A (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX2016007965A (es) Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MX2016012779A (es) Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX2014007169A (es) Tratamiento de trastorno autoinmune al usar agonistas de rxr.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX348933B (es) Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
NZ704496A (en) Retinoids and use thereof
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
WO2014146111A3 (en) Analgesic compounds and methods of use
MY175326A (en) Product and method for treating diarrhea
MX2016001104A (es) Composiciones para tratar engrosamiento de la piel.
MX2013013182A (es) Tratamiento de la mastitis.
MX2016005567A (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamin a (nmda).
MX2016002308A (es) Tratamiento del mieloma multiple.
MX2016002307A (es) Tratamiento para el cancer.
MX2012010006A (es) Agonistas de a3ar para el tratamiento de uveitis.

Legal Events

Date Code Title Description
FG Grant or registration